Nanion’s Patchliner exceptionally well received by academic ion channel core facilities

München, (PresseBox) - The new year has started well for Nanion; in the first weeks of 2011 more than five Patchliners were sold and shipped to academic institutions intended for advanced ion channel research and screening projects, and are soon to be followed by the first SyncroPatch 96 shipment and installation.

The Patchliner, a highly versatile patch clamp screening platform for increased throughput, has been on the market since 2006. Patchliner customers are evenly distributed over pharmaceutical industry, contract research organizations and academic institutions because of the flexibility and increased throughput of the platform.

Again highlighted by the recent sales, the Patchliner is a much appreciated tool for academic research, mainly because of the high data quality obtained with the platform, and its vast experimental freedom.

Together with three additional Principal Investigators, Dr. Todd Scheuer and Dr. William Catterall invested in both the Patchliner and the Port-a-Patch to form a core facility for ion channel screening and research at the University of Washington, Seattle, USA.

Dr. Todd Scheuer, Research Professor at the Department of Pharmacology, University of Washington, Seattle, says:

"We invested in the Patchliner because of its great experimental flexibility. The diversity of our research projects requires a platform capable of high performance with a multitude of ion channels and cells, as well as experimental possibilities such as action potential- or primary cell recordings."

In the southern hemisphere, Dr. Steven Petrou, Associate Director at the Florey Neuroscience Institute, and Associate Professor at the Centre for Neuroscience, The University of Melbourne, Australia, invested in multiple Patchliners for the ion channel core facility there.

Dr. Steven Petrou, says:

"We recently bought several Patchliners to cover the needs of our neuroscience research projects and to establish an ion channel core facility for the wider ion channel research community. Indeed, the Patchliner has unique experimental features including temperature control, internal perfusion and fast solution exchange. This in combination with supporting giga-Ohm seals and having a throughput corresponding to 100 dose responses per day convinced us that Patchliner will be of great use in our current, but also future research projects."

Dr. Niels Fertig, CEO of Nanion says:

"We are of course very pleased with this year's sales trend, which reflects the customers' appreciation of our high fidelity patch clamp platform and the strong scientific background of our support team. As a consequence, we have expanded the US-office to match the demand for demonstration and to cover possible assay support. Further, the installation of another five Patchliners in top-notch academic laboratories confirms its strength and unparalleled experimental features."

Nanion Technologies GmbH

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established two highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the patch clamp technique. Following the successful market introduction of two automated patch clamp devices, the Port-a-Patch (2004) and the Patchliner (2006), Nanion now introduces a massively parallel patch clamp platform, the SyncroPatch 96. Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).

Contact details:
Niels Fertig, CEO, Phone: +49 89 2189 97972, Email:, Web:

Press releases you might also be interested in

Weitere Informationen zum Thema "Forschung und Entwicklung":

KI im Unternehmen: das Für und Wider

Auf der ei­nen Sei­te er­leich­tert der Ein­satz von Künst­li­cher In­tel­li­genz (KI) den Ar­beit­sall­tag, stei­gert die Ef­fi­zi­enz und führt zu ei­ner bes­se­ren Kun­den­bin­dung. Für Un­ter­neh­men er­ge­ben sich je­doch auch neue Scha­den- und Haf­tungss­ze­na­ri­en.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.